GSC
NBSE

Ground Swell Capital’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Ground Swell Capital’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$8K Buy
+3
New +$9.92K 0.02% 1204

Other funds holding NBSE

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ground Swell Capital's NBSE Position: Q3 2014 in Review

Ground Swell Capital opened a new position in NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2014: 3 shares worth $8K. The stake represents 0.02% of the portfolio and ranks #1204 among its holdings.

52 funds tracked by Wall St. Rank hold NBSE as of Q3 2014.

  • Ground Swell Capital held 3 shares of NeuBase Therapeutics, Inc. Common Stock worth $8K as of Q3 2014.
  • NeuBase Therapeutics, Inc. Common Stock was a new Ground Swell Capital position in Q3 2014.
  • NeuBase Therapeutics, Inc. Common Stock made up 0.02% of Ground Swell Capital's portfolio in Q3 2014, its #1204 holding.
  • 52 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.